Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 16, 2016OncotargetOpen Access

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use

View Full Paper
Ask AI
Bookmark
Share

Authors

HPHarshnira Hitesh PataniInstitute of Structural and Molecular BiologyTBTom D. BunneyInstitute of Structural and Molecular BiologyNTNethaji ThiyagarajanUniversity of Bath

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Patani et al. (2016) studied this question.

synapsesocial.com/papers/6a0cd67cbae89ae0106fb066https://doi.org/10.18632/oncotarget.8132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Amplification of chromosomal segment 4q12 in non-small cell lung cancer2009 · 83 citations
  2. 2The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study2015 · 77 citations
  3. 3FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor2012 · 364 citations
  4. 4The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors2013 · 140 citations
  5. 5Cracking the Molecular Origin of Intrinsic Tyrosine Kinase Activity through Analysis of Pathogenic Gain-of-Function Mutations2013 · 57 citations